McClarren Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

McClarren Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-60	Closed	-$5K	–	427
2023 Q4	$5K	Hold	60	–	–	﹤0.01%	301
2023 Q3	$4K	Hold	60	–	–	﹤0.01%	289
2023 Q2	$4K	Hold	60	–	–	﹤0.01%	293
2023 Q1	$4K	Hold	60	–	–	﹤0.01%	281
2022 Q4	$4K	Hold	60	–	–	﹤0.01%	286
2022 Q3	$4K	Buy	+60	New	+$5.06K	﹤0.01%	269
2022 Q2	–	Sell	-60	Closed	-$5K	–	294
2022 Q1	$5K	Hold	60	–	–	﹤0.01%	235
2021 Q4	$7K	Buy	+60	New	+$7.24K	﹤0.01%	256

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

McClarren Financial Advisors's XBI Position: Q1 2024 in Review

McClarren Financial Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 60 shares — an estimated $5K sold.

McClarren Financial Advisors first reported a position in XBI in Q4 2021 and held it in 8 quarters. The position peaked at $7K in Q4 2021. 782 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

McClarren Financial Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
McClarren Financial Advisors sold 60 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $5K.
McClarren Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 8 quarters.
McClarren Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $7K in Q4 2021.
782 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on McClarren Financial Advisors's 13F filing for Q1 2024, filed 3 May 2024.